- Home
- ZVRA
as 12-20-2024 4:00pm EST
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | CELEBRATION |
| Market Cap: | 511.6M | IPO Year: | 2015 |
| Target Price: | $21.20 | AVG Volume (30 days): | 550.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.20 - $9.76 | Next Earning Date: | 11-12-2024 |
| Revenue: | $24,489,000 | Revenue Growth: | 47.85% |
| Revenue Growth (this year): | -24.36% | Revenue Growth (next year): | 383.29% |
Stock Insider Trading Activity of Zevra Therapeutics Inc. (ZVRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watton Corey Michael | ZVRA | Director | Oct 11 '24 | Buy | $7.92 | 500 | $3,957.65 | 1,500 |
Latest Zevra Therapeutics Inc. News
ZVRA Breaking Stock News: Dive into ZVRA Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Zevra Therapeutics to Join Nasdaq Biotechnology Index
GlobeNewswire
5 days ago
Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Pharma Voice
14 days ago
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
GlobeNewswire
16 days ago
Zevra Therapeutics Announces Organizational Changes
Simply Wall St.
16 days ago
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake
GlobeNewswire
a month ago
Zevra Therapeutics to Participate at Upcoming Investor Conferences
TipRanks
a month ago
Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease
GlobeNewswire
a month ago
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
Compare ZVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVRA Zevra Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.